chartexchange

NYMXF
NYMOX PHARM CORP
stockOTC

EODNov 18, 2026
0.0109USD-63.667%(-0.0191)514
Loading…
Loading…
986,615
Healthcare
Biotechnology
HQ
Nassau, Bahamas
Previous Close
$0.03
Beta
10.36
52-Week High
$0.20 2026-05-27
52-Week Low
$0.00 2026-09-10
SMA 50
$0.03
SMA 200
$0.06
Avg. Vol 10D
41,951
Avg. Vol 30D
24,430
Avg. Vol 90D
32,439
Relative Vol
0.02
55.06M
380
NYMXF Profile

nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.

NYMXF Performance
PeriodPriceDateChangeBeta
1W0.042026-11-12-68.86%-69.638
1M0.032026-10-20-65.94%15.444
3M0.002026-08-19+5350.00%64.637
6M0.072026-05-19-84.43%29.752
1Y0.092025-11-19-87.37%10.364
2Y0.052024-11-19-78.24%—
NYMXF Stock Summary

NYMOX PHARM CORP (OTC:NYMXF) stock price today is $0.01, and today's volume is 514. NYMXF is down 63.667% today. The 30 day average volume is 24,430. NYMXF market cap is $986,615 with 90.52M shares outstanding.